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Introduction: Rare FGF23-producing mesenchymal tumors lead to paraneoplastic
tumor- induced osteomalacia (TIO) present ing with phosphate wast ing,
hypophosphatemia, chronic hypomineralization of the bone, fragility fractures and
muscle weakness. Diagnosis of TIO requires exclusion of other etiologies and careful
search for a mesenchymal tumor that often is very small and can appear anywhere in the
body. Surgical removal of the tumor is the only definitive treatment of TIO. Surgical
complications due to chronic hypophosphatemia are not well recognized.
Case Description: The current case describes severe fragility fractures in a 58-year-old
woman, who lost her ability to walk and was bedridden for two years. First, the initial
diagnostic laboratory work-up did not include serum phosphorus measurements,
second, the suspicion of adverse effects of pioglitazone as an underlying cause delayed
correct diagnosis for at least two years. After biochemical discovery of hyperphosphaturic
hypophosphatemia at a tertiary referral centre, a FGF23-producing tumor of the mandible
was discovered on physical examination, and then surgically removed. Postoperatively,
severe hypophosphatemia and muscle weakness prolonged the need for ventilation
support, intensive care and phosphate supplementation. After two years of rehabilitation,
the patient was able to walk short distances. The tumor has not recurred, and serum
phosphate concentration has remained within normal limits during 3.5 years of follow-up.
Conclusions: The case report illustrates knowledge gaps in the diagnostic work-up of
rare causes of low bone mass and fragility fractures. Compared to other low phosphate
conditions, surgical recovery from TIO-induced hypophosphatemia warrants special
attention. Increased alkaline phosphatase concentration may indicate impaired
postsurgical recovery due to prolonged hypophosphatemia, underlining the need for
proactive perioperative correction of hypophosphatemia.
Keywords: tumor-induced hypophosphatemia, intensive care, oncogenic osteomalacia, perioperative
hypophosphatemia, surgical complications, tumor-induced osteomalacia, fibroblast growth factor 23n.org June 2021 | Volume 12 | Article 6861351
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Tumor-induced osteomalacia (TIO) is a rare paraneoplastic
syndrome caused by increased Fibroblast growth factor 23
(FGF23) secretion, typically from a small mesenchymal tumor.
In TIO, FGF23 excess drives phosphate wasting and leads to
hypophosphatemic oncogenic osteomalacia. Patients typically
present with severe symptoms of bone pain, skeletal muscle
myopathy, multiple fractures or pseudofractures, skeletal
deformities, and impaired quality of life (1, 2).
The diagnosis of TIO is challenging but surgical removal of
the phosphaturic mesenchymal neoplasm potentially cures the
patient (1, 3). Although the significance of transient phosphate
disorders during surgery and intensive care are extensively
described, the specific problems associated with chronic
hypophosphatemia due to a FGF23-producing tumor in
postsurgical patients are poorly described in the literature. The
current case underlines the need for careful presurgical planning
and active phosphate replacement in severe hypophosphatemia
caused by TIO to prevent prolonged need for ventilation
assistance, and intensive care.CASE DESCRIPTION
A 58-year-old female had a three year-history of multiple stress
fractures and muscle weakness. Her medical history included
well-controlled type 2 diabetes (HbA1c 43 mmol/mol) for nearly
20 years. Her BMI was 39 kg/m2 and she was on metformin,
long-acting insulin and pioglitazone. She was a current smoker
with a smoking history of 27 pack years and her dietary calcium
intake was considered normal. Skeletal growth had been normal,
and she had not suffered from bone fractures or abnormal
skeletal pains previously. She did not have a family history of
skeletal, metabolic or hormonal disorders.
Three years prior to diagnosis the patient presented with
multiple fragility fractures and increasing bone pain. Fractures
were found in the vertebrae (Figure 1A), right femur, sacrum
and lateral condyle of the right tibia, and in the left talus. She
complained of progressive muscle weakness and diffuse bone
pains in her back and lower extremities.
One year later, dual-energy X-ray absorptiometry (DXA)
demonstrated osteopenic bone mineral density (T-scores of
lumbar vertebrae 3-4 and the femoral neck were -0.8 SD,
and -2.3 SD, respectively). Basic biochemistry in primary care
was unremarkable (data not shown). Pioglitazone treatment,
initiated four years before the first fragility fracture, was
suspected to underlie the multiple, low-intensity fractures and
therefore discontinued. At this point, type 2 diabetes was
considered as another predisposing factor.Abbreviations: ATP, adenosine triphosphate; BMI, body mass index; CKPAN,
Pan-cytokeratin; CPAP, continuous positive airway pressure; CT, computed
tomography; DXA, dual-energy absorptiometry; EIA, enzyme immunoassay;
FGF23, fibroblast growth factor 23; MRI, magnetic resonance imaging; TIO,
tumor-induced osteomalacia.
Frontiers in Endocrinology | www.frontiersin.org 2During the year before the diagnosis, she suffered from a
stress fracture of the left femur with significant dislocation
(Figure 1C), which was treated with total hip arthroplasty, as
well as a stress fracture of the right femur that was treated with an
intramedullary nail (Figure 1D). Within the next months, she
also suffered from stress fractures of the right distal femur, tibia
(Figure 1B) and humerus.
A year before correct diagnosis of TIO, teriparatide, calcium
carbonate (1000 mg daily) and cholecalciferol (20 µg daily)
supplementations were initiated to enhance recovery of bone
strength after pioglitazone treatment.
The patient was referred to the University Hospital Endocrine
Unit. At this time point, the patient had not been able towalk for two
years, was bedridden andhad lost 30 kg ofweight (from106 to 78kg),
and she needed constant pain medication (oxycodone 50 mg,
gabapentin 1800 mg and paracetamol 3 grams daily). Biochemical
tests revealed hypophosphatemia, combined with high serum
FGF23-concentration (C-terminal, EIA-method, MVZ Labor Dr.
Limbach&Kollegen,Heidelberg,Germany), inappropriately normal
24-hour urinary phosphate secretion, and increased serum alkaline
phosphatase concentration (Table 1). Alphacalcidol (0.25 µg twice
daily) and phosphate supplementation (Phosphate Sandoz 500 mg
twice daily, reduced dose due to diarrhea) were started. Calcium
carbonate 1000 mg and cholecalciferol 20 µg daily were continued
and teriparatide was discontinued. A bone biopsy from the
iliac crest demonstrated osteomalacia. Genetic testing for
hypophosphatemia [mutations in the DMP-1, ENPP1, FGF23,
PHEX and SLC34A3 genes (4)] was negative. Computed
tomography (CT) of the thorax and abdomen revealed no
tumors. An additional, complete physical examination revealed a
palpablemass in the rightmandible. Ultrasound andCT confirmed
a tumor with invasive growth in the right mandible (Figure 1E).
Cytologic analysis of a fine needle aspiration taken from the tumor
demonstrated myoepithelial-like cells.
After the diagnosis was confirmed, the tumor of the right
mandible was operated. Histopathological examination of
formalin-fixed and paraffin-embedded slides demonstrated a
2.6 cm phosphaturic mesenchymal tumor with multinucleated,
osteoclast-like cells (Figure 1F), with minimum tumor free
resection margins of 0.5 mm. The Ki-67 proliferation index in
hot spots was 10-15%. Immunohistochemical studies showed
positive vimentin staining (Figure 1G) but negative CD34, EMA,
and CKPAN stainings, compatible with a phosphaturic
mesenchymal tumor and the diagnosis of TIO (5). The
histologic samples were re-evaluated by an expert pathologist
in the National Institutes of Health, USA.
Postoperatively, the patient needed prolonged treatment of 10
days in the intensive care unit. Both intravenous and p.o. phosphate
supplementations were warranted to correct for severe
hypophosphatemia (Table 2). After surgery, the concentration of
serum ionized calcium remained in the normal range, 1.16-1.25
mmol/l (reference range 1.15-1.30 mmol/l). Administration of
calcium carbonate 1000 mg and cholecalciferol 20 µg daily was
continued. Due to muscle weakness, the patient was dependent on
mechanical ventilation for four days. Thereafter, she needed
continuous positive airway pressure (CPAP) through aJune 2021 | Volume 12 | Article 686135
Ryhänen et al. Case Report: Prolonged Hypophosphatemia After Surgery of TIOtracheostomy.During that time, tomaintain sufficientbloodpressure
levels, norepinephrine infusion had to be maintained for one week
after surgery. She was on enteral nutrition during the postoperative
days 1-11 (1500kcal daily fromthirdpostoperativeday).On the third
postoperative day, the patient presentedwith respiratory alkalosis for
six hours after fiberoptic bronchoscopy, with a pH of 7.52-7.60 and
low/normal pCO2 (3.6-4.9 kPa), and elevated pO2 (13.2-59.8 kPa),
base excess (BE) (2.5-5.7 mmol/l) and bicarbonate (HCO3)
concentrations (27-30 mmol/l) (reference ranges 7.35-7.45, 4.5-6.0
kPa, 9.3-12.3 kPa, -2.5-2.5 mmol/l and 22-24 mmol/l, respectively).
From the fourth postoperative day onwards, arterial pH remainedFrontiers in Endocrinology | www.frontiersin.org 3within normal range. The patient was decanylated one week
postoperatively (Table 2). She received subcutaneous short-acting
insulin (4-12 units daily) for hyperglycaemia.
Phosphate supplementations were administered for eight
weeks. The patient received oxandrolone for one week because
of extreme weakness and lack of spontaneous respiratory activity
in order to improve muscle function and the recovery of lean
body mass (6). Skeletal and limb pains relieved soon, and muscle
weakness alleviated within the succeeding months. The patient
was able to take a few steps after four months of rehabilitation.
After two years of rehabilitation, the patientwas able towalk 100
meterswithawalkerand shorterdistanceswithout anyhelp. Shehas
not suffered fromany further fractures or bone pains. After surgery,
serum phosphate concentration has remained normal. Serum
FGF23 concentrations decreased immediately after the operation
and have remained slightly increased (Figure 2). Due to the
vertebral fractures, DXA of the spine was unreliable.LITERATURE SEARCH
We identified MeSH-terms (https://www.nlm.nih.gov/mesh/
meshhome.html) for possible studies reporting postoperative
complications during surgery for TIO. The identified MeSH-
terms were searched in PubMed/MEDLINE database from 1966
to February 28, 2021. No publications describing postoperative
prolonged hypophosphatemia, surgical complications, or
prolonged need for intensive care or mechanical ventilation
support in TIO patients were found. The electronic search was
supplemented by manually searching reference lists of recent
review articles that revealed two case reports of postoperative




FIGURE 1 | Radiological images of the fragility fractures diagnosed before the diagnosis of TIO. Compression fractures and kyphoscoliosis of the spine in CT (A),
MRI scan showing fragility fracture of the lateral condyle of the right tibia (B), X-ray of the fragility fracture of left femoral neck (C) and X-ray of pelvis showing
arthroplasty of the left hip and osteosynthesis performed after fragility fractures in right femoral shaft and lateral condyle after surgery (D). CT scan of the tumor in the



















Creatinine (50-90 mmol/l) 60 47 60







FGF23 (26-110 kRU/l) 2410 279 364
PINP (13-116 mg/l) 188 (578, 6 mo after
surgery)
63PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; PINP, Procollagen type 1
N-propeptide.June 2021 | Volume 12 | Article 686135
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Here, we describe a 58-year old patient with TIO, who presented
with prolonged postoperative need for phosphate supplements and
ventilation support in the intensive care unit because of severe,
persistent hypophosphatemia and respiratory muscle weakness.
The decrease in postoperative phosphate levels mimicked a
transient hungry bone syndrome-like event that resolved after
normalization of bone markers including alkaline phosphatase.
According to the literature search, persistent hypophosphatemia
complicating the recovery fromsurgical treatment ofTIOhasnot been
described previously. In our patient, the post-surgical prolonged
hypophosphatemia and muscle weakness required i.v. and p.o.Frontiers in Endocrinology | www.frontiersin.org 4phosphate supplementation up to eight weeks, despite complete
removal of the mesenchymal tumor and later permanent
normophosphatemia. According to previous publications, after
excision of the mesenchymal tumor, serum phosphate and FGF23
concentrations usually return to normal within the first five post-
surgical days, with gradual alleviation of symptoms. During the
recovery phase, the skeleton is actively remineralizing and patients
maytransiently require supplemental calciumtopreventhypocalcemia
and secondary hyperparathyroidism (1, 7). Chong et al. (7) describe
that the severity of the metabolic bone disease correlates with the
serum alkaline phosphatase concentrations, and that kidney
phosphate reabsorption may recover slowly. In our patient, severe
hypophosphatemia was associated with progressive increase in serum
alkaline phosphatase concentrations and bone markers, and loss
of muscle strength. The bone biopsy revealed severe osteomalacia,
which is a typical histological finding in hyperphosphaturic
hypophosphatemia (8). In the present case, a multifactorial
background probably best explains hypophosphatemia, including
gradual recovery of renal proximal tubular dysfunction and
increased phosphate uptake by the skeleton leading to a transient
hungrybone syndrome-like decrease inpostoperative phosphate levels
but the precise mechanisms remains unclear (9). A limitation in our
case includes lack ofmeasurements of tubularmaximumreabsorption
of phosphate and 1,25-(OH)2D immediately post-operatively.
However, other causes for hypophosphatemia such as alkalosis or
the use of norepinephrine or insulin only briefly contributed to
hypophosphatemia during the ICU stay and adequate nutrition was
maintained to prevent the re-feeding syndrome (10).
Severe hypophosphatemia is a well-known risk factor for
delayed postoperative recovery. In our patient, other factors that
could have contributed to late weaning from assisted ventilation
include smoking, obesity anddiabetes. Phosphate is essential for the
synthesis of ATP (adenosine triphosphate) and 2,3-
diphosphoglycerate, both of which are critical for the regulationFIGURE 2 | Timeline showing serum phosphate and FGF23 (C-terminus)
concentrations at diagnosis and postoperatively. Time of surgery is marked
with the black triangle and X-axis presents the time in months relative to
surgery. Reference ranges are 0.76-1.41 mmol/l, and 26-110 kRU/l are
marked to the y-axes with a bar, respectively.TABLE 2 | Serum phosphate, ionized calcium and PTH concentrations, phosphate substitution and during 10-day postoperative intensive care.
Number of days
after surgery













0.45 1.19 47 none Phosphate 1000 mg no
Surgery not measured 1.27 52 mmol none ventilator
Day 1 not measured 1.26 52 mmol none ventilator
Day 2 0.27 (morning)
0.91 (evening)
1.24 78 mmol none ventilator
Day 3 0.38 1.15 85 mmol none ventilator
Day 4 0.59 1.20 92 mmol Phosphate 500 mg ventilator#
Day 5 0.56 1.21 62 mmol Phosphate 500 mg extubated,
noninvasive ventilation
(CPAP)
Day 6 0.66 1.22 62 mmol Phosphate 500 mg CPAP
Day 7 not measured 1.25 69 42 mmol Phosphate 500 mg CPAP
Day 8 0.85 1.26 none Phosphate 1000 mg CPAP
Day 9 not measured 1.24 none Phosphate 1000 mg Oxygen mask
Day 10 1.00 1.28 none Phosphate 1000 mg Oxygen mask
Day 30 1.30 1.26 73 none Phosphate 1000 mg NoneJune 2021*reference ranges 0.76-1.71 mmol/l, 1.15-1.30 mmol/l, 15-65 ng/l, respectively. #oxandrolone was started and given for one week.
CPAP, Continuous positive air pressure.
Calcium carbonate supplementation of 1000 mg daily remained stable during the pre- and postoperative period.| Volume 12 | Article 686135
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patients, hypophosphatemia is associatedwith increasedmorbidity,
including longer dependence on mechanical ventilation and
prolonged hospitalization. Hypophosphatemia decreases
contractility of the diaphragm, left ventricular function, insulin
sensitivity, and functions of the central nervous system, which
predispose to postoperative complications such as respiratory
insufficiency, increased incidence of ventricular tachycardia,
impaired glucose metabolism, seizures, and coma (12–17).
Respiratory alkalosis, hyperglycemia, insulin and cathecholamines
may further worsen hypophosphatemia during intensive care (16–
18). These risks are relevant for patients with TIO, in whom the
treatment aims at curative surgery.
Although the phosphate concentration normalized within
two months, the C-terminal FGF23 concentration remained
slightly elevated despite biochemical and physical recovery
(Figure 2). Previous literature suggests that this may reflect an
alteration in FGF23 processing that increases the biologically
inactive FGF23 fraction (19).
We performed a literature search to summarize the current
knowledge of surgical complications and identified only three case
reports of postoperative problems associated with TIO (20–22),
which emphasize the need for careful assessment of cardiovascular
and respiratory status both pre- and postoperatively. However, in
these cases, postoperative recovery was only mildly disturbed. Our
patient presented with long-term myopathy and, postoperatively,
needed 10 days of treatment in the intensive care unit due to
difficulties in weaning from mechanical ventilation and
hypotension, despite continuous intravenous and oral phosphate
supplementations. After normalization of plasma phosphate,
muscle weakness persisted for months and rehabilitation is still
ongoing. In patients with TIO, careful planning of the postsurgical
management includingmeasurements of alkaline phosphatase and
phosphorus concentrations is thus essential.
Fragility fractures are a diagnostic challenge. They are more
common after menopause and in patients with type 2 diabetes,
both of which increase bone fragility by enhancing the cortical
porosity and decreasing the cortical area and bone material
strength (23). Glitazone treatment is associated with an
augmented risk of fragility fractures, including both upper and
lower limb, as well as hip fractures. Both rosiglitazone and
pioglitazone appear equally likely to adversely affect bone
health (24–26). In our patient, treatment with pioglitazone for
4.5 years before referral to the Endocrine University Hospital
Unit was suspected to underlie the multiple fragility fractures. To
our knowledge, glitazones are not known to cause osteomalacia
in bone histology. In animal studies, histomorphometric analysis
of the trabecular bone of the proximal tibia demonstrate
increased fat content and number of adipocytes during
rosiglitazone administration. In addition, osteoblast activity is
decreased and osteoclast activity increased (27, 28). It is unlikely
that type 2 diabetes or pioglitazone use alone could have caused
the clinical scenario in the present case, which initially was
dominated by multiple severe fractures caused by minimal
trauma. Speculatively, these factors may have caused additional
bone frailty on top of long term TIO.Frontiers in Endocrinology | www.frontiersin.org 5The current case demonstrates the importance of thorough
assessment of basic low-cost laboratory tests in patients with low
energy fragility fractures, since the delay in the diagnosis was partly
due to lackofdeterminationsof serumphosphate concentrations.A
recent large series of 144 patients with TIO demonstrates that 95%
of patients are initially misdiagnosed, or characteristic laboratory
findings are neglected (29). Importantly, current European
guidance for the diagnosis and management of osteoporosis in
postmenopausal women (30) recommend measurement of serum
phosphate and alkaline phosphatase to exclude a disease which can
mimic osteoporosis, such as any type of osteomalacia. In our
patient, other differential diagnostic testing included exclusion of
vitamin D deficiency, chronic renal and/or hepatic diseases and,
genetic hyperphosphaturic diseasesdue tomutations in theDMP-1,
ENPP1, FGF23, PHEX and SLC34A3 genes. In addition to the
clinical picture, the age of our patient, the results of biochemical
testing, thefindingof impairedbonemineralizationonbonebiopsy,
as well as the significantly increased serum FGF23 concentrations
were consistent with the diagnosis of TIO (1, 30).
Given their small size, FGF23-producing mesenchymal tumors
are difficult to detect with anatomic imaging (radiography,
ultrasound, CT and MRI). In our patient, physical examination
revealed a tumor in left mandible region that was confirmed by
ultrasound. A biopsy was obtained but is not generally
recommended because it may lead to tumor seeding (31).
Currently, a stepwise approach is recommended, including head
to toe functional imaging with Ga-68 DOTATATE PET/CT, the
sensitivity of which is better than that of 18F-FDG PET/CT (32).
Some centers use selective venous sampling of FGF23, which may
be indicated in special situations (33, 34).Most tumors reside in the
extremities, while tumors of the maxilla or mandible have been
reported less frequently. In a report of 39 patients fromBeijing, 56%
of the tumors were found in the lower extremities, 5% in the upper
extremities, 3% in the hip, 31% in the head, and 5% in the thoracic
region (35). Eight of 12 tumors found in theheadwere located in the
mandible or the maxilla. Two tumors were detected on physical
examination, and one of them was located in the mandible (35). In
another series of 17 Chinese patients, 53% of the tumors were
revealed on physical examination, one of which was found in the
mandible (36). In the current case, the mesenchymal phosphaturic
tumor involving the mandible was detected by palpation, which
underlines the importance of thorough basic physical examination.
Phosphaturic mesenchymal tumors are characterized by
distinct molecular genetic features with high prevalence of
fibronectin 1 (FN1)-FGFR1 fusion gene and less frequently a
FN1-FGF1 fusion, which are detected in in 42% and 6% of cases,
respectively and may aid the pathologic diagnosis (37). We could
not obtain a molecular genetic testing of these fusion gene
rearrangements in our case. However, the histologic samples
were re-evaluated by an expert pathologist in the National
Institutes of Health, USA, to confirm the histological diagnosis.
The current case illustrates knowledge gaps in the diagnostic
work-up of rare causes of low bone mass and fragility fractures.
Phosphorus was measured only after referral to a tertiary center.
Pioglitazone use possibly further worsened the clinical course and
certainly delayed the diagnosis ofTIO inour patient.We emphasizeJune 2021 | Volume 12 | Article 686135
Ryhänen et al. Case Report: Prolonged Hypophosphatemia After Surgery of TIOthe need to recognize that severe myopathy, longstanding
presurgical hypophosphatemia and elevated alkaline phosphatase
concentrations may indicate major difficulties in postsurgical
weaning from the ventilator, and delayed recovery. In such cases,
perioperative hypophosphatemia should be corrected proactively.
In the future, novel FGF23-antagonists may prove useful in the
preoperative treatment of severe hypophosphatemia when other
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